- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
- Rapid review of TA1088.
- Process:
- Rapid Review Standard
- ID number:
- 6652
Provisional Schedule
- Expected publication:
- 17 March 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Incyte (ruxolitinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Gene People
- Vitiligo Society
- Vitiligo Support UK
- Professional groups
- British Association of Dermatologists
- British Dermatological Nursing Group
- Royal College of Physicians
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 February 2026 - 24 February 2026 | Final draft guidance |
| 24 February 2026 | In progress. Rapid review |
| 05 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual